Physician profile
Timothy S Rummel
NPI 1598760217
$7,768.09
in general payments reported to CMS, 2019-2025
39 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $909 · 2021: $555 · 2022: $427 · 2023: $735 · 2024: $1,879 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Travel and Lodging: $1,935 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.76 |
| Travel and Lodging | $1,935.46 |
| Education | $272.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $1,784.82 | 2024-2025 | Remede System |
| Inspire Medical Systems, INC. | $1,484.18 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $866.02 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Harmony Biosciences LLC | $716.54 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $375.12 | 2019-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $335.97 | 2019-2025 | |
| Grifols USA, LLC | $221.71 | 2019-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $219.18 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Axsome Therapeutics, INC. | $175.00 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $152.32 | 2023-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.62 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $114.46 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $110.60 | 2019-2024 | Opsumit |
| Gilead Sciences, INC. | $99.14 | 2021-2023 | |
| Lilly USA, LLC | $74.14 | 2025 | Zepbound |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Rummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.